E-mail| Contact Us| Volunteer| Make A Gift| En Español| Employees



  • Take Control of your Smoking History
  • World-class cancer care made LG Health his top destination
 
 





Learn More

Ann B. Barshinger Cancer Institute



 
Read the Oncology Program Annual Report 2013
 
Oncology Clinical Trials

Oncology Clinical Trials


New hope in the fight against cancer

Thanks to a history of clinical trials research, people with cancer are living longer and with a better quality of life than ever before. Cancer research is advancing at a fast pace and, as a result, researchers are able to develop targeted therapies that are changing the standards of care and saving lives.
 

Some patients may fear that enrollment in a clinical trial means they may receive no treatment at all. The reality is that patients in studies receive either the best treatment currently known for their specific cancer, or a new, and possibly more effective, therapy. Placebos are never used in place of treatment when an existing therapy exists.
 

The Ann B. Barshinger Cancer Institute participates in numerous studies sponsored by the National Cancer Institute through groups such as the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group and the American College of Surgeons Oncology Group.

 

Current oncology treatment trials open for participation:


Site Study Title
BREAST

CREP

 

Familial Breast Cancer Studies

PALLAS -AFT-05 ABCSG 42 BIG 14-03

 

PALLAS: Palbociclib Collaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

NRG
NRG-BR003

 

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node-Negative Triple-Negative Invasive Breast Cancer.

Metamorph
In conjunction with Penn

 

Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

GI

Astellas
8951-CL-0301

 

Phase III, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus MFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

GU

Calithera
CX-839-005

 

A Randomized, Double-blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

GYN

NRG
NRG-GY009

 

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin And CTEP-Supplied Atezolizumab(IND#134427) Versus Pegulated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

HEME

Celgene
AZA-MDS-006

 

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

BMS CA 209-602

 

An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

LUNG

BMS  CA209-9LA

 

A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-small Cell Lung Cancer

OTHER

ECOG-ACRIN
EAY131-MATCH

 

Molecular Analysis for Therapy Choice (MATCH)


If you have any questions contact oncology research at 717-544-0511

Updated 6/21/2018

 



 
Find A Doctor
Advanced Search
Call 1-888-LGH-INFO
 


Learn More





 

Contact Us:

1-888-LGH-INFO (544-4636) Have a question?
Follow us online.